HALOZYME THERAPEUTICS, INC. (HALO) /
The cash flow of HALOZYME THERAPEUTICS, INC. over the past 10 years
Chart HALOZYME THERAPEUTICS, INC.: operating cash flow, capital expenditures, free cash flow, fiscal 2016–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, HALOZYME THERAPEUTICS, INC.'s operating cash flow was $651.56M and its capital expenditures $6.97M, leaving free cash flow of $644.59M. Free cash flow was above zero in 7 of the 10 years shown. It ranged from -$89.46M in fiscal 2019 to $644.59M in fiscal 2025. Capital expenditures were highest in fiscal 2023, at $15.29M.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | $651.56M | $6.97M | $644.59M |
| 2024ended Dec 31, 2024 | $479.06M | $10.7M | $468.37M |
| 2023ended Dec 31, 2023 | $388.57M | $15.29M | $373.28M |
| 2022ended Dec 31, 2022 | $240.11M | $4.81M | $235.3M |
| 2021ended Dec 31, 2021 | $299.44M | $1.46M | $297.98M |
| 2020ended Dec 31, 2020 | $55.45M | $2.5M | $52.95M |
| 2019ended Dec 31, 2019 | -$85.42M | $4.04M | -$89.46M |
| 2018ended Dec 31, 2018 | -$49.5M | $4.66M | -$54.16M |
| 2017ended Dec 31, 2017 | $134.05M | $1.35M | $132.7M |
| 2016ended Dec 31, 2016 | -$50.38M | $3.14M | -$53.52M |
Fiscal years as HALOZYME THERAPEUTICS, INC. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on HALOZYME THERAPEUTICS, INC.
- The revenue of HALOZYME THERAPEUTICS, INC.
- The profitability of HALOZYME THERAPEUTICS, INC.
- The debt of HALOZYME THERAPEUTICS, INC.
- All of HALOZYME THERAPEUTICS, INC.'s financials, charted
Companies of a similar size
- ALLEAllegion plc
- PNFPPINNACLE FINANCIAL PARTNERS, INC.
- JHXJAMES HARDIE INDUSTRIES plc
- SUISUN COMMUNITIES, INC
- BZKANZHUN LIMITED
Not investment advice. This page shows what HALOZYME THERAPEUTICS, INC. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.